Skip to main content Skip to footer

Philadelphia Life Sciences Team

Life Sciences Real Estate. Accelerated.

For emerging and established life sciences companies, speed to market is your goal - but with an historically low supply of suitable building inventory, the challenges of identifying, negotiating and executing a real estate solution are a hurdle to getting there. For owners, if you want to provide a viable option for this growth market, you need to speak the language and understand the financial and operational requirements of these specialized tenants.

 

Between them, the team of Joe Fetterman, Mike Brown and Clifford Brechner have specialized in life sciences real estate for 40 years, assisting clients with changing real estate requirements at key stages of growth. We offer extensive experience with strategic planning, site selection, transaction structuring and lease negotiation and documentation. In addition, our team is supported by the Colliers International Life Sciences Practice group covering the principal life science clusters across the US. We partner regularly with economic incentives consultants, process engineers and design/build specialists to support our clients' lab and manufacturing facility requirements.


We have experience with cGMP process manufacturing facilities in a variety of scales including:

  • Biologics Manufacturing
  • CAR-T and UCAR-T Manufacturing
  • Vector Manufacturing
  • Regenerative Cell Manufacturing
  • OSD Manufacturing
  • Parenteral Manufacturing

We also have experience with a variety of research & development facilities including:

  • Large Molecule Discovery
  • Small Molecule Discovery
  • Potent Compound Development Labs
  • Kilo Labs
  • Analytical Labs
  • AAALAC Certified Vivarium Facilities
Philadelphia Life Sciences Team Photo: Joe Fetterman and Michael J. Brown

Our Expertise in Action

UCART Manufacturing Facility Site Selection

Colliers International recently structured a lease for Cellectis, a Paris based clinical-stage biopharmaceutical company, to create an 82,000 square foot commercial-scale manufacturing facility named IMPACT (Innovative Manufacturing Plant for Allogeneic Cellular Therapies) in Raleigh, North Carolina, for clinical and commercial production of Cellectis’ leading allogeneic UCART products.

With products in clinical trials, the Cellectis team was under time pressure to identify and build out a US manufacturing plant that would enable them to meet their manufacturing and marketing timeline. The search was limited to the East Coast to enable easy access to Paris. Key factors informing the search were depth of skilled workforce, cost of living, suitable building configuration and infrastructure...read more

PhiladelphiaLifeSciencestab523x523cellectis2

Disposition of a Clinical Scale Biologics Manufacturing Facility

The Colliers Life Sciences Group was tasked with packaging and selling the NEOSE Technologies process facility, a 50,000-square-foot biologics manufacturing facility with two 3,000 Litre Mammalian Cell Manufacturing Sites, back within the industry to a company with a pipeline of products in the clinical stages of development. The facility was already 10 years old at the date of sale.

We identified through substantial research the names of those companies who were in Phases I, II and III with a strategy to develop and manufacture their product internally and not contract with a CMO....read more

PhiladelphiaLifeSciencestab523x523neose2

Regenerative Cell Manufacturing Site Search

Tengion is a development-stage regenerative medicine company that required a first-of-its-kind facility utilizing current good manufacturing practices (cGMP) to manufacture autologous cells for the regeneration of bladder cells. The building required spaces for quality assurance, quality control, tissue culture and an open sterile manufacturing room for an incubator farm to produce the replacement bladders.

Tengion hired the Colliers team to perform a site-selection survey with a comparative analysis between two states, Pennsylvania and North Carolina. The site had to be free of vibrations that might impact the analytical equipment, have the potential to accommodate 2,000 amps of power, offer access to dark fiber and provide sufficient equivalent dwelling units (EDUs) to...read more

PhiladelphiaLifeSciencestab523x523tengion

Science Park at Yale in New Haven, CT

The global Life Sciences Practice Group at Colliers spans multiple markets. In Connecticut, LSPG retains sole leasing responsibility for Science Park at Yale, a large research park that is the former manufacturing center of the Winchester Repeating Arms Company.

Colliers has worked with ownership and tenants to keep the complex occupied, productive and vibrant for a decade. To date, more than 150,000 square feet in the complex has been leased at a value of more than $20 million. Long term representation of the property has included transactions for lab and vivarium space with companies in various phases of their development cycle...read more

Life Sciences Team Science Park at Yale research park

Client Experience

lifesciencesteampageclientsservedlogo2cellectis250x196
lifesciencesteampageclientsservedlogo2universitycitysciencecenter250x196
lifesciencesteampageclientsservedlogo2almac250x196
lifesciencesteampageclientsservedlogo2cherokeepharmaceuticals250x196
lifesciencesteampageclientsservedlogo2biomedrealtytrust250x196
lifesciencesteampageclientsservedlogo2assemblybiosciences250x196
PhiladelphiaLifeSciencesclientsservedlogowistar250x196
lifesciencesteampageclientsservedlogo2neose250x196
lifesciencesteampageclientsservedlogo2viropharma250x196
lifesciencesteampageclientsservedlogo2glaxosmithkline250x196
lifesciencesteampageclientsservedlogo2tengion250x196
lifesciencesteampageclientsservedlogo2venatorx250x196

Stay Ahead with Industry Leading Research

Nov 23, 2020

Converging for Cures | Philadelphia Life Sciences 2020 Market Report

Learn how Philadelphia is coming together as a Life Sciences ecosystem with the emergence of clear “neighborhoods” - each with a flight path for continued development and expansion.
Read More
Jun 24, 2020

Mid-Year Update: COVID-19 Impact on the Life Sciences Real Estate Sector

Lab productivity is recovering. COVID-related investigations are on a fast track. Expansion requirements are back on pace, even exceeding pre-COVID levels.
Read More
Mar 24, 2020

SARS-CoV-2 Impact on the Life Sciences Real Estate Sector

Learn the five trends facing the lab real estate sector as we react to a global pandemic in a new Colliers Life Sciences whitepaper report.
Read More
Feb 25, 2020

In-House or Outsource? Considerations for Biotechs at the Drug Manufacturing Crossroads

In house or outsource to a CDMO? Five considerations for pre-clinical and clinical drug development companies facing critical manufacturing decisions, authored by Joseph Fetterman of the Colliers Life Sciences Practice Group.
Read More

Market news

Stay in Touch


Stay ahead of the curve with our in-depth research reports, innovative thought leadership pieces, educational content and more covering the life sciences sector in the Greater Philadelphia region. Subscribe to our emails.

Join our email list

How can we help you?

* Required Field